Overview
- Roche, which announced the Tecentriq SC rollout Thursday, says the subcutaneous dose is now available nationwide and already in use for more than 100 patients.
- India’s drug regulator recently cleared the shot for adjuvant and metastatic non‑small cell lung cancer, and doctors say roughly half of patients qualify based on PD‑L1 test results.
- The company lists a price of about ₹3.7 lakh per vial, with many patients needing around six cycles, and it is offering Blue Tree financial support while the drug is also listed under the CGHS scheme.
- Nurses can give the 1,800 mg dose under the skin in about seven minutes, which hospitals say can free infusion chairs, cut travel and waiting time, and allow care in daycare settings.
- The formulation uses Halozyme’s Enhanze technology with rHuPH20 to speed absorption, and Roche is importing supply from Germany as it discusses Phase IV post‑marketing studies in India.